Ironwood Pharmaceuticals
IRWD
260 hedge funds and large institutions have $1.5B invested in Ironwood Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 85 increasing their positions, 84 reducing their positions, and 43 closing their positions.
1,107% more call options, than puts
Call options by funds: $241M | Put options by funds: $20M
23% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 43
4.35% more ownership
Funds ownership: 105.68% → 110.03% (+4.4%)
4% more funds holding
Funds holding: 251 → 260 (+9)
1% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 84
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less capital invested
Capital invested by funds: $1.89B → $1.5B (-$387M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$87.4M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$42.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$42.3M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$31.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$28.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$65.7M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$49.7M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$35.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$25.4M |
| 5 |
BlackRock
New York
|
-$22.1M |
IRWD Hedge Fund Activity: Q1 2024 in Review
260 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2024, worth a combined $1.5B — down 21% from $1.89B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new IRWD positions and 43 closed out — a net gain of 10 holders — while 85 added to existing stakes and 84 trimmed.
The largest buyer was Pacer Advisors, opening a new position worth an estimated $87.4M. The largest seller was Credit Suisse, cutting an estimated $65.7M.
- 260 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2024, up from 251 in Q4 2023.
- Funds reported $1.5B of Ironwood Pharmaceuticals stock for Q1 2024, down 21% quarter-over-quarter.
- 53 funds opened new Ironwood Pharmaceuticals positions in Q1 2024 and 43 closed out, a net change of +10 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2024 was Pacer Advisors, an estimated $87.4M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2024 was Credit Suisse, an estimated $65.7M sold.
Based on aggregated 13F filings for Q1 2024.